Investment Rating - The report maintains a "Buy" rating for the company [2] Core Insights - The company reported a revenue of 859 million yuan for H1 2025, representing a year-on-year growth of 42.4%, and a net profit of 392 million yuan, up 26.6% year-on-year [7] - The company is focusing on expanding its product matrix, particularly in the medical device sector, and has launched new products aimed at high-end consumers [7] - The report anticipates a sales acceleration starting in Q3 2025, driven by strong demand in the skincare segment and the introduction of new products [7] Financial Data and Profit Forecast - Total revenue projections for 2025, 2026, and 2027 are 2,339 million yuan, 3,213 million yuan, and 3,943 million yuan respectively, with year-on-year growth rates of 62.1%, 37.4%, and 22.7% [6] - The forecasted net profit for the same years is 1,042 million yuan, 1,474 million yuan, and 1,867 million yuan, with corresponding growth rates of 42.3%, 41.5%, and 26.6% [6] - The company’s gross margin is projected to be 89.8% in 2025, slightly decreasing over the following years [6] Business Segmentation - The revenue breakdown for H1 2025 shows that single medical devices accounted for 75.1% of total revenue, followed by functional skincare products at 14.1% [7] - The company has introduced new products such as the HiveCOL gel, which targets the medical aesthetics market, and has seen significant growth in its functional skincare segment [7] Market Expansion - The company is actively expanding into overseas markets, with successful registrations for its products in Thailand and market access in the US and Saudi Arabia for its high-end skincare brand [7]

Market Overview - The medical beauty sector experienced a decline of 0.21% on August 13, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - ST Meigu closed at 3.15 with no change, trading volume of 88,100 shares, and a transaction value of 27.62 million yuan [1] - Huaxi Biological closed at 53.60, down 0.09%, with a trading volume of 40,900 shares and a transaction value of 218 million yuan [1] - Aimeike closed at 186.00, down 0.29%, with a trading volume of 32,400 shares and a transaction value of 600 million yuan [1] - Jinbo Biological closed at 301.49, down 0.49%, with a trading volume of 8,955 shares and a transaction value of 271 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 63.94 million yuan from institutional investors, while retail investors had a net inflow of 61.61 million yuan [1] - Speculative funds recorded a net inflow of 2.34 million yuan [1] Additional Stock Data - ST Meigu reported a net outflow of 3.73 million yuan, a decrease of 13.52% [2] - Huaxi Biological had a net outflow of 16.99 million yuan, a decrease of 7.78% [2] - Aimeike experienced a net outflow of 43.22 million yuan, a decrease of 7.20% [2]

Core Viewpoint - Securities firms have provided "buy" ratings for over 20 A-share listed companies on August 13, focusing on industries such as liquor, transportation equipment, complete automobiles, bioproducts, consumer electronics, and auto parts [1] Group 1: Company Ratings - Kweichow Moutai received significant attention from securities firms, with five reports on August 13, ranking first among recommended stocks. Guojin Securities projected net profits of 93.4 billion, 98.8 billion, and 105.4 billion yuan for 2025-2027, with year-on-year growth rates of +8.4%, +5.8%, and +6.6% respectively, maintaining a "buy" rating [4] - Yanjing Beer was also highlighted, with five reports in the past month. Pacific Securities forecasted revenue growth rates of 6%, 5%, and 4% for 2025-2027, and net profit growth rates of 44%, 19%, and 11% respectively, assigning a target price of 14.58 yuan and a "hold" rating [4] - Chuanfeng Power, a leader in the all-terrain vehicle industry, received attention from four securities firms, ranking third among recommended stocks on August 13 [5] Group 2: Industry Insights - The liquor industry, particularly Kweichow Moutai and Yanjing Beer, is experiencing strong interest from analysts, indicating a positive outlook for major players in this sector [4] - The transportation equipment sector, represented by Chuanfeng Power, is benefiting from high-end market trends and product innovation, suggesting growth potential [5] - Other companies such as BYD, Jinbo Biological, Industrial Fulian, Fuda Co., Rongbai Technology, China Unicom, and Aobi Zhongguang have also garnered attention from multiple securities firms, indicating a broad interest across various industries [5]

Investment Rating - The investment rating for the company is "Accumulate" [3][17]. Core Views - The company demonstrates steady revenue growth, balancing product expansion and brand promotion, with significant R&D advantages expected to lead to innovative products in gynecology, hair care, and serious medical fields [1]. - The company has established a mature branding strategy and is building a global system for its products, with multiple patents approved in various regions [9]. Financial Summary - Total revenue is projected to grow from 780 million in 2023 to 3,534 million by 2027, reflecting a compound annual growth rate (CAGR) of 28.2% [2][10]. - Net profit attributable to the parent company is expected to increase from 300 million in 2023 to 1,814 million in 2027, with a CAGR of 29.4% [2][10]. - Earnings per share (EPS) is forecasted to rise from 2.61 yuan in 2023 to 15.77 yuan in 2027 [2][10]. - The return on equity (ROE) is projected to remain strong, starting at 31.4% in 2023 and declining to 34.2% by 2027 [2][10]. Market Data - The target price for the company's stock is set at 402.74 yuan [3]. - The stock has a 52-week price range of 151.90 to 577.50 yuan [4]. - The total market capitalization is approximately 34.86 billion yuan [4]. Business Segments - The medical device segment reported revenue of 708 million in the first half of 2025, a year-on-year increase of 33.41% [9]. - The functional skincare segment saw a significant revenue increase of 152.39%, reaching 121 million in the same period [9]. - The raw materials segment experienced a modest growth of 12.40%, with revenue of 27 million [9]. Operational Highlights - The company has successfully obtained patents for its collagen products in Brazil and FDA certifications for several skincare products in the U.S. [9]. - Marketing strategies include collaborations with leading medical institutions and participation in academic summits and international expos to enhance brand recognition [9].

Summary of Key Points Core Viewpoint - The investment and financing landscape of the medical beauty injection materials industry in China is relatively mature, with a significant number of investment events and a focus on scientific research and technology services. Group 1: Financing Status - As of June 2025, there have been 39 investment events in the medical beauty injection materials industry, indicating a mature investment environment [2][4]. - The majority of financing events are concentrated in Shandong and Jiangsu provinces, with Shandong having 8 events and Jiangsu 7 events [4]. Group 2: External Investment Layout - Representative companies in the medical beauty injection materials industry have engaged in numerous external investment events, primarily focusing on scientific research and technology services, which account for approximately 58% of their investments [14][13]. - Other sectors of investment include manufacturing (18%) and wholesale and retail (8%) [14]. Group 3: Mergers and Acquisitions - The level of mergers and acquisitions in the medical beauty injection materials industry is relatively low, with notable participation from real estate companies. For instance, Lushang Development acquired 100% of Shandong Furuida Pharmaceutical Group in 2018 to enter the medical beauty sector [16].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% compared to the benchmark index [4]. Core Insights - The company achieved a revenue of 859 million yuan in H1 2025, representing a year-on-year growth of 42.43%, while the net profit reached 392 million yuan, up 26.65% year-on-year [1]. - The gross margin for H1 2025 was 90.68%, a decrease of 0.9 percentage points, and the net profit margin was 45.5%, down 5.84 percentage points [1]. - The sales expense ratio increased to 21.05%, up 3.18 percentage points, attributed to higher personnel costs and promotional expenses [1]. - The medical device segment grew by 33.41% year-on-year, generating 708 million yuan in revenue, while the skincare segment saw a significant increase of 152.39%, reaching 121 million yuan [2]. - The company launched the HiveCOL collagen product and received medical device registration in Thailand, enhancing its international market presence [3]. Financial Performance - The company is projected to achieve earnings per share (EPS) of 12.11, 16.28, and 20.54 yuan for the years 2025, 2026, and 2027, respectively, with corresponding price-to-earnings (PE) ratios of 26, 20, and 16 times [4]. - Revenue forecasts for 2025, 2026, and 2027 are 2.133 billion yuan, 2.790 billion yuan, and 3.503 billion yuan, respectively, with year-on-year growth rates of 47.84%, 30.79%, and 25.56% [6]. - The company’s return on equity (ROE) is expected to be 44.11%, 39.84%, and 35.70% for the years 2025, 2026, and 2027 [6].

北交所股票中，8月12日共有138只股获融资净买入，净买入金额在百万元以上的有43只，锦波生物融资 净买入额居首，当日净买入3355.98万元，其次是鼎智科技、曙光数创，融资净买入金额分别为841.16万 元、796.91万元，融资净买入金额居前的还有国源科技、利通科技、星图测控等。融资净卖出金额居前 的股票为科力股份、佳先股份、万源通等，融资净卖出金额分别为917.84万元、624.55万元、622.81万 元。 证券时报·数据宝统计显示，截至8月12日，北交所股票中，融资余额居前的为锦波生物、贝特瑞、艾融 软件，最新融资余额分别为3.67亿元、1.56亿元、1.49亿元，从最新融资余额占流通市值比例看，算术 平均值为1.21%，最新融资余额占流通市值比例居前的有巨能股份、胜业电气、万源通等，占比分别为 3.89%、3.70%、3.52%。 | 代码 | 简称 | 8月12日涨跌幅 | 最新融资余额 | 较上一日增加 | 占流通市值比例 | 所属行 | | --- | --- | --- | --- | --- | --- | --- | | | | （%） | （万元） | （万元） | （%） | 业 ...

Core Viewpoint - Jinbo Biological's strong financial performance in the first half of 2025 highlights its growth potential in the collagen protein market, driven by innovative product development and strategic partnerships [1][2][3]. Financial Performance - In the first half of 2025, Jinbo Biological achieved operating revenue of 859 million yuan, a year-on-year increase of 42.43%, and a net profit attributable to shareholders of 392 million yuan, up 26.65% [1]. - The company plans to distribute a cash dividend of 1.15 billion yuan, equivalent to 10.0 yuan per 10 shares [1]. Revenue Sources - Revenue growth was primarily driven by medical device products, which generated 708 million yuan, a 33.41% increase year-on-year, with a gross margin of 95.04% [2]. - Functional skincare products contributed 121 million yuan, reflecting a significant growth of 152.39% year-on-year, with a gross margin of 70.78% [2]. Research and Development - Jinbo Biological increased its R&D expenditure to 45.8 million yuan, accounting for 5.33% of operating revenue, marking an 85.43% increase compared to the previous year [2]. - The company collaborates with top research institutions, including Fudan University and Sichuan University, to enhance its R&D capabilities [2]. Product Innovation - The company launched the world's first "injection-type recombinant type III humanized collagen gel," approved by the National Medical Products Administration, showcasing its innovative capabilities [3]. - This product utilizes self-assembly and self-crosslinking technology, aimed at correcting mid-facial volume loss and contour defects [3]. Strategic Partnerships - Jinbo Biological has attracted a significant strategic investor, Yangshengtang Co., Ltd., planning to raise up to 2 billion yuan through a private placement [3]. - Following the issuance, Yangshengtang will hold over 5% of Jinbo Biological's shares, enhancing collaboration in R&D, production, and commercialization [3]. Market Outlook - The collagen protein market in China is expected to grow rapidly, with a projected compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [1][4]. - The increasing focus on skin health and medical aesthetics is driving the demand for recombinant humanized collagen in various applications [4].

Investment Rating - The investment rating for Shanxi Jinbo Bio-Pharmaceutical is maintained at OUTPERFORM with a target price of Rmb 405.10, indicating a potential upside of 26.6% from the current price of Rmb 302.98 [2][19]. Core Insights - In H1 2025, the company's revenue reached Rmb 708 million, representing a year-on-year growth of 42.4%. However, the growth rates for both revenue and profit have slowed down compared to previous periods [3][14]. - The medical device segment's revenue in H1 2025 was Rmb 708 million, up 33.4% year-on-year, driven by the sales of implantable products [3][14]. - The functional cosmetics segment saw a significant increase in revenue, reaching Rmb 121 million, up 152.4% year-on-year, primarily due to the growth of its own brands [3][14]. - The company plans to distribute dividends of Rmb 10 per 10 shares, with a payout ratio of 29.3% [3][14]. Financial Performance - The gross margin for H1 2025 was 90.7%, a decrease of 90 basis points year-on-year, while the net profit attributable to the parent company was Rmb 390 million, up 26.7% year-on-year [4][15]. - The sales expense ratio increased significantly in Q2 2025, leading to a slowdown in profit growth [4][15]. - The company expects its revenue to reach Rmb 2.17 billion, Rmb 2.92 billion, and Rmb 3.72 billion for 2025, 2026, and 2027, respectively, with growth rates of 50.2%, 34.8%, and 27.3% [19]. Product Development and Innovation - The company achieved three major breakthroughs with its new injectable product, which enhances safety and manufacturing processes [6][16]. - The recombinant human-sourced collagen new material project is expected to be terminated, leading to an impairment provision of Rmb 9.11 million [6][16]. Market Expansion - In H1 2025, the company obtained a medical device registration permit in Thailand and established two new subsidiaries for pharmaceutical manufacturing and business expansion in Hong Kong [7][17]. Equity Incentive Plan - The 2025 equity incentive plan impacts approximately Rmb 11 million, with performance targets set for net profits over the next three years [8][18].

截至2025年8月12日收盘，锦波生物股价报302.98元，较前一交易日下跌17.05元，跌幅5.33%。当日成 交量为21265手，成交金额达6.44亿元。 锦波生物是一家专注于重组人源化胶原蛋白与抗HPV生物蛋白技术研发与产业化的国家级专精特新"小 巨人"企业。公司产品广泛应用于皮肤科、妇科、外科等多个医疗领域，尤其在医学抗衰老和医疗美容 领域具有较强市场竞争力。 根据公司最新披露的2025年半年报显示，上半年锦波生物实现营业收入8.59亿元，同比增长42.43%；归 母净利润3.92亿元，同比增长26.65%。值得关注的是，公司研发投入大幅增加，上半年研发费用达到 4579.62万元，同比增长85.43%，研发费用占营业收入比重提升至5.33%。 风险提示：本文所提及个股仅作客观分析，不构成投资建议。市场有风险，投资需谨慎。 来源：金融界 ...